The structure of NS-398 bound to cyclooxygenase-2

Journal of Structural Biology

Volumn 176, Issue 2, 2011, Pages 254-258

  Vecchio, Alex J ^a,b   Malkowski, Michael G ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cyclooxygenase; Nonsteroidal anti inflammatory drugs; NS 398; Prostaglandin H 2 synthase; X ray crystal structure

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; FLURBIPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG STRUCTURE; ENZYME CONFORMATION; PRIORITY JOURNAL; SYNCHROTRON RADIATION;

AMINO ACID MOTIFS; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; NITROBENZENES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SULFONAMIDES;

MURINAE;

EID: 80053385334     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2011.07.019     Document Type: Article

References (43)

1. Blobaum A.L., Marnett L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50:1425-1441.
2. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 54:905-921.
3. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
4. DeWitt D.L. Cox-2-selective inhibitors: the new super aspirins. Mol. Pharmacol. 1999, 55:625-631.
5. Dodson E.J., Winn M., Ralph A. Collaborative Computational Project, number 4: providing programs for protein crystallography. Methods Enzymol. 1997, 277:620-633.
6. Duggan K.C., Walters M.J., Musee J., Harp J.M., Kiefer J.R., et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J. Biol. Chem. 2010, 285:34950-34959.
7. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
8. Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:72-82.
9. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47:55-59.
10. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 1993, 24:105-110.
11. Garavito R.M., Malkowski M.G., DeWitt D.L. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 2002, 68-69:129-152.
12. Gierse J.K., McDonald J.J., Hauser S.D., Rangwala S.H., Koboldt C.M., et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 1996, 271:15810-15814.
13. Greig G.M., Francis D.A., Falgueyret J.P., Ouellet M., Percival M.D., et al. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 1997, 52:829-838.
14. Guo Q., Wang L.H., Ruan K.H., Kulmacz R.J. Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J. Biol. Chem. 1996, 271:19134-19139.
15. Harman C.A., Turman M.V., Kozak K.R., Marnett L.J., Smith W.L., et al. Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J. Biol. Chem. 2007, 282:28096-28105.
16. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Marnett A.B., Kozak K.R., et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. USA 2000, 97:925-930.
17. Kiefer J.R., Pawlitz J.L., Moreland K.T., Stegeman R.A., Hood W.F., et al. Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 2000, 405:97-101.
18. Kozak K.R., Rowlinson S.W., Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 2000, 275:33744-33749.
19. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644-648.
20. Langer G., Cohen S.X., Lamzin V.S., Perrakis A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 2008, 3:1171-1179.
21. Laskowski R.A., Moss D.S., Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 1993, 231:1049-1067.
22. Loll P.J., Picot D., Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 1995, 2:637-643.
23. Luong C., Miller A., Barnett J., Chow J., Ramesha C., et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 1996, 3:927-933.
24. Marnett L.J. The COXIB experience. a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 2009, 49:265-290.
25. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., et al. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
26. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53:240-255.
27. Picot D., Loll P.J., Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994, 367:243-249.
28. Potterton E., Briggs P., Turkenburg M., Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 2003, 59:1131-1137.
29. Potterton L., McNicholas S., Krissinel E., Gruber J., Cowtan K., et al. Developments in the CCP4 molecular-graphics project. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2288-2294.
30. Rieke C.J., Mulichak A.M., Garavito R.M., Smith W.L. The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J. Biol. Chem. 1999, 274:17109-17114.
31. Rouzer C.A., Marnett L.J. Cyclooxygenases: structural and functional insights. J. Lipid Res. 2009, 50(Suppl.):S29-S34.
32. Rowlinson S.W., Kiefer J.R., Prusakiewicz J.J., Pawlitz J.L., Kozak K.R., et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 2003, 278:45763-45769.
33. Schneider C., Boeglin W.E., Brash A.R. Identification of two cyclooxygenase active site residues, leucine 384 and glycine 526, that control carbon ring cyclization in prostaglandin biosynthesis. J. Biol. Chem. 2004, 279:4404-4414.
34. Selinsky B.S., Gupta K., Sharkey C.T., Loll P.J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001, 40:5172-5180.
35. Sidhu R.S., Lee J.Y., Yuan C., Smith W.L. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 2010, 49:7069-7079.
36. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
37. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002, 68-69:95-114.
38. Vecchio A.J., Malkowski M.G. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J. Biol. Chem. 2011, 286:20736-20745.
39. Vecchio A.J., Simmons D.M., Malkowski M.G. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J. Biol. Chem. 2010, 285:22152-22163.
40. Wada M., DeLong C.J., Hong Y.H., Rieke C.J., Song I., et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 2007, 282:22254-22266.
41. Wang J.L., Carter J., Kiefer J.R., Kurumbail R.G., Pawlitz J.L., et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors - part I: the first clinical candidate. Bioorg Med Chem Lett 2010, 20:7155-7158.
42. Wong E., Bayly C., Waterman H.L., Riendeau D., Mancini J.A. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 → Arg and Ile523 → val mutation. J. Biol. Chem. 1997, 272:9280-9286.
43. Yu M., Ives D., Ramesha C.S. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 1997, 272:21181-21186.